A Longitudinal Study of AFP Trajectories and Clinical Outcomes in Intermediate-Stage Hepatocellular Carcinoma After Hepatectomy

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Liu G, Ouyang Q, Xia F, et al. Alpha-fetoprotein response following transarterial chemoembolization indicates improved survival for intermediate-stage hepatocellular carcinoma. HPB (Oxford). 2019;21(1):107–113. doi:10.1016/j.hpb.2018.06.1800
   PubMed Web of Science ®Google Scholar
• Liu B, Shang X, Shi JY, et al. Early alpha-fetoprotein response is associated with survival in patients with HBV-related hepatocellular carcinoma receiving lenvatinib. Front Oncol. 2022;12:807189.
   PubMed Web of Science ®Google Scholar
• Mishra G, Dev A, Paul E, et al. Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation. BMC Cancer. 2020;20(1):483. doi:10.1186/s12885-020-06806-4
   PubMed Web of Science ®Google Scholar
• Yang SL, Liu LP, Yang S, et al. Preoperative serum alpha-fetoprotein and prognosis after hepatectomy for hepatocellular carcinoma. Br J Surg. 2016;103(6):716–724. doi:10.1002/bjs.10093
   PubMed Web of Science ®Google Scholar
• Romano F, Chiarelli M, Garancini M, et al. Rethinking the Barcelona clinic liver cancer guidelines: intermediate stage and Child-Pugh B patients are suitable for surgery? World J Gastroenterol. 2021;27(21):2784–2794. doi:10.3748/wjg.v27.i21.2784
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Kobayashi T, Hashimoto M, et al. Significance of liver resection for intermediate stage hepatocellular carcinoma according to subclassification. BMC Cancer. 2021;21(1):668. doi:10.1186/s12885-021-08421-3
   PubMed Web of Science ®Google Scholar
• Prince D, Liu K, Xu W, et al. Management of patients with intermediate stage hepatocellular carcinoma. Ther Adv Med Oncol. 2020;12:1758835920970840. doi:10.1177/1758835920970840
   Web of Science ®Google Scholar
• Hyun MH, Lee Y-S, Kim JH, et al. Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: a meta-analysis of high-quality studies. Hepatology. 2018;68(3):977–993. doi:10.1002/hep.29883
   PubMed Web of Science ®Google Scholar
• Li XL, Zhu V, Cai H, et al. Postoperative alpha-fetoprotein response predicts tumor recurrence and survival after hepatectomy for hepatocellular carcinoma: a propensity score matching analysis. Surgery. 2019;165(6):1161–1167.
   PubMed Web of Science ®Google Scholar
• Rungsakulkij N, Suragul W, Mingphruedhi S, et al. Prognostic role of alpha-fetoprotein response after hepatocellular carcinoma resection. World J Clin Cases. 2018;6(6):110–120. doi:10.12998/wjcc.v6.i6.110
   PubMed Web of Science ®Google Scholar
• Lu L, Shen L, Wu Z, et al. Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: a longitudinal, retrospective, multicentre, cohort study. EClinicalMedicine. 2022;47:101391. doi:10.1016/j.eclinm.2022.101391
   PubMedGoogle Scholar
• Shen L, Zeng Q, Guo P, et al. Dynamically prognosticating patients with hepatocellular carcinoma through survival paths mapping based on time-series data. Nat Commun. 2018;9(1):2230.
   PubMedGoogle Scholar
• Lu L, Zheng P, Wu Z, et al. Hepatic resection versus transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: a cohort study. Front Oncol. 2021;11:618937. doi:10.3389/fonc.2021.618937
   PubMed Web of Science ®Google Scholar
• Pan YX, Sun XQ, Hu ZL, et al. Prognostic values of alpha-fetoprotein and des-gamma-carboxyprothrombin in hepatocellular carcinoma in china: an analysis of 4792 patients. J Hepatocell Carcinoma. 2021;8:657–670. doi:10.2147/JHC.S316223
   PubMed Web of Science ®Google Scholar
• Zhong JH, Ke Y, Gong WF, et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg. 2014;260(2):329–340. doi:10.1097/SLA.0000000000000236
   PubMed Web of Science ®Google Scholar
• Shen JY, Li C, Wen TF, et al. Alpha fetoprotein changes predict hepatocellular carcinoma survival beyond the Milan criteria after hepatectomy. J Surg Res. 2017;209:102–111. doi:10.1016/j.jss.2016.10.005
   PubMed Web of Science ®Google Scholar
• Lu L, Zheng P, Pan Y, et al. Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving atezolizumab plus bevacizumab: a secondary analysis of IMbrave150 study. Br J Cancer. 2023;129(4):620–625. doi:10.1038/s41416-023-02334-7
   PubMed Web of Science ®Google Scholar
• Zhu AX, Dayyani F, Yen CJ, et al. Alpha-fetoprotein as a potential surrogate biomarker for atezolizumab + bevacizumab treatment of hepatocellular carcinoma. Clin Cancer Res. 2022;28(16):3537–3545. doi:10.1158/1078-0432.CCR-21-3275
   PubMed Web of Science ®Google Scholar
• Zhang Q, Shang L, Zang Y, et al. α-Fetoprotein is a potential survival predictor in hepatocellular carcinoma patients with hepatitis B selected for liver transplantation. Eur J Gastroenterol Hepatol. 2014;26(5):544–552. doi:10.1097/MEG.0000000000000029
   PubMed Web of Science ®Google Scholar
• Kim HS, Park JW, Jang JS, et al. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study. J Clin Gastroenterol. 2009;43(5):482–488. doi:10.1097/MCG.0b013e318182015a
   PubMed Web of Science ®Google Scholar
• Li MS, Li PF, He SP, et al. The promoting molecular mechanism of alpha-fetoprotein on the growth of human hepatoma Bel7402 cell line. World J Gastroenterol. 2002;8(3):469–475. doi:10.3748/wjg.v8.i3.469
   PubMed Web of Science ®Google Scholar